Evaluation of Etanercept for Treatment of Reactive Infectious Mucocutaneous Eruption

Melanie M Miller; Sonia Kamath; Meagan Hughes; Nicole Harter; Minnelly Luu

doi:10.1001/jamadermatol.2020.5166

Evaluation of Etanercept for Treatment of Reactive Infectious Mucocutaneous Eruption

JAMA Dermatol. 2021 Feb 1;157(2):230-232. doi: 10.1001/jamadermatol.2020.5166.

Authors

Melanie M Miller¹, Sonia Kamath^{1

2}, Meagan Hughes^{1

2}, Nicole Harter^{1

2}, Minnelly Luu^{1

2}

Affiliations

¹ Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles.
² Department of Pediatric Dermatology, Children's Hospital Los Angeles, Los Angeles, California.

Abstract

This cohort study evaluates the association of etanercept treatment with outcomes of reactive infectious mucocutaneous eruption in hospitalized children and adolescents.

MeSH terms

Adolescent
Child
Child, Preschool
Cohort Studies
Erythema Multiforme / drug therapy*
Erythema Multiforme / pathology
Etanercept / administration & dosage*
Exanthema / drug therapy
Exanthema / pathology
Female
Humans
Immunosuppressive Agents / administration & dosage*
Male
Mycoplasma pneumoniae / isolation & purification
Retrospective Studies

Substances

Immunosuppressive Agents
Etanercept